<DOC>
	<DOC>NCT01375998</DOC>
	<brief_summary>This study is a regulatory post marketing surveillance in Japan, and it is a local prospective and observational study of patients who have received YAZ for dysmenorrhea. The objective of this study is to assess safety and efficacy of using YAZ in clinical practice. A total 3,000 patients will be recruited and followed 3 years since starting YAZ administration.</brief_summary>
	<brief_title>YAZ Post-marketing Surveillance in Japan</brief_title>
	<detailed_description />
	<mesh_term>Dysmenorrhea</mesh_term>
	<criteria>Patients who received YAZ for dysmenorrhea Additional criteria for QOL questionnaire Patient informed consent Patients who are contraindicated based on the product label Additional criteria for QOL questionnaire Six months or less after treatment of estrogen or estrogen combination drug</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>YAZ</keyword>
	<keyword>Dysmenorrhea</keyword>
</DOC>